1. Home
  2. HIMX vs ADPT Comparison

HIMX vs ADPT Comparison

Compare HIMX & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Himax Technologies Inc.

HIMX

Himax Technologies Inc.

HOLD

Current Price

$20.63

Market Cap

2.1B

Sector

Technology

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$13.06

Market Cap

2.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HIMX
ADPT
Founded
2001
2009
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.1B
2.3B
IPO Year
2006
2019

Fundamental Metrics

Financial Performance
Metric
HIMX
ADPT
Price
$20.63
$13.06
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$17.78
AVG Volume (30 Days)
4.9M
1.5M
Earning Date
05-07-2026
05-05-2026
Dividend Yield
3.23%
N/A
EPS Growth
N/A
63.89
EPS
N/A
N/A
Revenue
N/A
$276,976,000.00
Revenue This Year
$14.94
$3.98
Revenue Next Year
$7.79
$22.72
P/E Ratio
$14.99
N/A
Revenue Growth
N/A
54.77
52 Week Low
$6.85
$8.50
52 Week High
$21.80
$20.76

Technical Indicators

Market Signals
Indicator
HIMX
ADPT
Relative Strength Index (RSI) 78.59 41.50
Support Level $7.63 $12.22
Resistance Level N/A $13.45
Average True Range (ATR) 1.44 0.75
MACD 0.89 -0.09
Stochastic Oscillator 89.48 5.20

Price Performance

Historical Comparison
HIMX
ADPT

About HIMX Himax Technologies Inc.

Himax Technologies Inc is a semiconductor solution provider dedicated to display imaging processing technologies. It operates through the Driver Integrated Circuit and Non-Driver Products segments. The majority of the firm's revenue is derived from the Driver Integrated Circuit segment. It offers display driver ICs and timing controllers used in TVs, laptops, monitors, mobile phones, tablets, digital cameras, virtual reality (VR) devices, and many other consumer electronics devices. It also designs and provides controllers for touch sensor displays, in-cell Touch and Display Driver Integration single-chip solutions, LED driver ICs, power management ICs, and scaler products for monitors and projectors. Geographically, it generates the majority of its revenue from China.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: